Search
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 1 of 1 items.
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12